FOXC1 expression predicts capecitabine efficacy in triple-negative breast cancer patients from the GEICAM_CIBOMA trial. - Rojo F; Taylor CR; Barrios C; Torrecillas L; Ruiz-Borrego M; Perez-Buira S; Bines J; Guerrero-Zotano A; Garcia-Saenz JA; Torres R; de la Haba-Rodriguez J; Ayala F; et al. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025)